JP7667139B2 - ウイルス感染症の治療のための組成物及び方法 - Google Patents

ウイルス感染症の治療のための組成物及び方法 Download PDF

Info

Publication number
JP7667139B2
JP7667139B2 JP2022514998A JP2022514998A JP7667139B2 JP 7667139 B2 JP7667139 B2 JP 7667139B2 JP 2022514998 A JP2022514998 A JP 2022514998A JP 2022514998 A JP2022514998 A JP 2022514998A JP 7667139 B2 JP7667139 B2 JP 7667139B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
complex
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022514998A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021046549A5 (https=
JP2022546609A (ja
JP2022546609A5 (https=
Inventor
バルコベック，ジェームズ，エム．
ベンセン，ダニエル，シー．
ボーチャード，アレン
ブレーディ，トーマス，ピー．
チェン，ジー－ヨン
コール，ジェイソン
ドー，クエン－クエン，トゥイ
デールマン，シモン
ジアン，ワンロン
ラム，タン
ノンコビッチ，アラン
タリ，レスリー，ダブリュ．
Original Assignee
シダラ セラピューティクス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シダラ セラピューティクス インコーポレーテッド filed Critical シダラ セラピューティクス インコーポレーテッド
Publication of JP2022546609A publication Critical patent/JP2022546609A/ja
Publication of JPWO2021046549A5 publication Critical patent/JPWO2021046549A5/ja
Publication of JP2022546609A5 publication Critical patent/JP2022546609A5/ja
Priority to JP2025065195A priority Critical patent/JP2025108559A/ja
Application granted granted Critical
Publication of JP7667139B2 publication Critical patent/JP7667139B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022514998A 2019-09-06 2020-09-08 ウイルス感染症の治療のための組成物及び方法 Active JP7667139B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025065195A JP2025108559A (ja) 2019-09-06 2025-04-10 ウイルス感染症の治療のための組成物及び方法

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201962897036P 2019-09-06 2019-09-06
US62/897,036 2019-09-06
US201962941405P 2019-11-27 2019-11-27
US62/941,405 2019-11-27
US201962948143P 2019-12-13 2019-12-13
US62/948,143 2019-12-13
US202062959857P 2020-01-10 2020-01-10
US62/959,857 2020-01-10
US202062966500P 2020-01-27 2020-01-27
US62/966,500 2020-01-27
US202062970491P 2020-02-05 2020-02-05
US62/970,491 2020-02-05
US202062984705P 2020-03-03 2020-03-03
US62/984,705 2020-03-03
US202062988304P 2020-03-11 2020-03-11
US62/988,304 2020-03-11
US202063032488P 2020-05-29 2020-05-29
US63/032,488 2020-05-29
US202063062377P 2020-08-06 2020-08-06
US63/062,377 2020-08-06
PCT/US2020/049772 WO2021046549A1 (en) 2019-09-06 2020-09-08 Compositions and methods for the treatment of viral infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025065195A Division JP2025108559A (ja) 2019-09-06 2025-04-10 ウイルス感染症の治療のための組成物及び方法

Publications (4)

Publication Number Publication Date
JP2022546609A JP2022546609A (ja) 2022-11-04
JPWO2021046549A5 JPWO2021046549A5 (https=) 2023-09-15
JP2022546609A5 JP2022546609A5 (https=) 2023-09-15
JP7667139B2 true JP7667139B2 (ja) 2025-04-22

Family

ID=74852729

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022514998A Active JP7667139B2 (ja) 2019-09-06 2020-09-08 ウイルス感染症の治療のための組成物及び方法
JP2025065195A Pending JP2025108559A (ja) 2019-09-06 2025-04-10 ウイルス感染症の治療のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025065195A Pending JP2025108559A (ja) 2019-09-06 2025-04-10 ウイルス感染症の治療のための組成物及び方法

Country Status (18)

Country Link
US (4) US20210220478A1 (https=)
EP (1) EP4025256A4 (https=)
JP (2) JP7667139B2 (https=)
KR (1) KR20220088527A (https=)
CN (2) CN114980933B (https=)
AU (2) AU2020342649B2 (https=)
CA (1) CA3153359A1 (https=)
CL (1) CL2022000531A1 (https=)
CO (1) CO2022003078A2 (https=)
CR (1) CR20220138A (https=)
EC (1) ECSP22026797A (https=)
IL (1) IL290792B1 (https=)
MX (1) MX2022002728A (https=)
PE (1) PE20221443A1 (https=)
PH (1) PH12022550505A1 (https=)
TW (1) TWI861205B (https=)
WO (1) WO2021046549A1 (https=)
ZA (1) ZA202203681B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210079278A (ko) 2018-09-06 2021-06-29 시다라 세라퓨틱스, 인코포레이티드 바이러스 감염의 치료를 위한 조성물 및 방법
TWI861205B (zh) 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法
AU2021210987A1 (en) * 2020-01-24 2022-08-04 Regeneron Pharmaceuticals, Inc. Protein-antiviral compound conjugates
US20230364251A1 (en) 2020-08-06 2023-11-16 Cidara Therapeutics, Inc. Methods for the synthesis of protein-drug conjugates
EP4192510A1 (en) 2020-08-06 2023-06-14 Cidara Therapeutics, Inc. Methods for the synthesis of protein-drug conjugates
US20240285786A1 (en) 2021-03-11 2024-08-29 Cidara Therapeutics, Inc. Protein-drug conjugates for antiviral therapy
WO2023125806A1 (zh) * 2021-12-30 2023-07-06 苏州爱科百发生物医药技术有限公司 用于预防和治疗病毒感染的偶联物及其用途
EP4551563A2 (en) * 2022-07-05 2025-05-14 Cidara Therapeutics, Inc. Fc conjugates including an inhibitor of cd73 and uses thereof
WO2025002421A1 (zh) 2023-06-29 2025-01-02 上海爱科百发生物医药技术股份有限公司 用于预防和治疗病毒感染的偶联物及其用途
WO2025064869A2 (en) * 2023-09-20 2025-03-27 Cidara Therapeutics, Inc. Compositions and methods for the treatment of cancer
WO2025119337A1 (zh) * 2023-12-08 2025-06-12 苏州拓界医药有限公司 一种抗病毒偶联物
WO2025157263A1 (zh) * 2024-01-26 2025-07-31 浙江养生堂天然药物研究所有限公司 偶联物及其制备方法和用途
WO2025230581A1 (en) * 2024-05-02 2025-11-06 Cidara Therapeutics, Inc. Fc conjugates and uses thereof
WO2026055183A1 (en) * 2024-09-03 2026-03-12 Vir Biotechnology, Inc Antiviral compositions and methods of using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004507564A (ja) 2000-09-08 2004-03-11 バイオタ、サイアンティフィック、マネージメント、プロプライエタリ、リミテッド 多価ノイラミニダーゼ阻害物質複合体
JP2005511609A (ja) 2001-11-09 2005-04-28 バイオタ、サイアンティフィック、マネージメント、プロプライエタリ、リミテッド 二量体化合物および抗ウイルス薬としてのそれらの使用
WO2018128826A1 (en) 2017-01-06 2018-07-12 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335368A (en) 1996-11-14 2001-08-31 Biota Scient Management Macromolecular compound with one or more neuraminidase binders, binds to the active site of influenza virus neuraminidase
US6495580B1 (en) 1998-01-29 2002-12-17 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
AUPP913999A0 (en) 1999-03-12 1999-04-01 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
SG122814A1 (en) 1999-06-28 2006-06-29 Janssen Pharmaceutica Nv Respiratory syncytial virus replication inhibitors
CA2495266A1 (en) 2002-08-09 2004-02-19 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
AU2006279304A1 (en) 2005-08-19 2007-02-22 Endocyte, Inc. Multi-drug ligand conjugates
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
EP2395992A2 (en) 2009-02-10 2011-12-21 The Scripps Research Institute Chemically programmed vaccination
CN103068378B (zh) 2010-05-10 2016-07-06 中央研究院 具有抗流感活性的扎那米韦膦酸酯同类物及其制备方法
MA34392B1 (fr) 2010-06-24 2013-07-03 Gilead Sciences Inc Pyrimidines en tant qu'agents antiviraux
RS55609B1 (sr) 2011-04-13 2017-06-30 Bristol Myers Squibb Co Fc fuzioni proteini koji sadrže nove linkere ili aranžmane
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US9834597B2 (en) 2012-09-21 2017-12-05 The Regents Of The University Of California Modified FC polypeptides, FC conjugates, and methods of use thereof
BR112015008325B1 (pt) 2012-10-16 2022-01-25 Janssen Sciences Ireland Uc Compostos antivirais contra o rsv, seu uso e composição farmacêutica que os compreende
EP3385277A1 (en) 2013-03-15 2018-10-10 F. Hoffmann-La Roche AG Il-22 polypeptides and il-22 fc fusion proteins and methods of use
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
JP6211195B2 (ja) 2013-08-12 2017-10-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 呼吸器合胞体ウイルス感染症の処置および予防のための新規アザ−オキソ−インドール
TWI671299B (zh) 2014-04-14 2019-09-11 愛爾蘭商健生科學愛爾蘭無限公司 作為ｒｓｖ抗病毒化合物之螺脲化合物
WO2017046625A1 (en) 2015-06-25 2017-03-23 Cube Biotech Gmbh New chelators for affinity purification of recombinant proteins
WO2018006063A1 (en) 2016-07-01 2018-01-04 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
KR20210079278A (ko) * 2018-09-06 2021-06-29 시다라 세라퓨틱스, 인코포레이티드 바이러스 감염의 치료를 위한 조성물 및 방법
EP3982994A4 (en) 2019-06-13 2023-10-04 Cidara Therapeutics, Inc. Compositions and methods for the treatment of respiratory syncytial virus
AU2020291469A1 (en) 2019-06-13 2022-02-10 Cidara Therapeutics, Inc. Compositions and methods for the treatment of human immunodeficiency virus
TWI861205B (zh) 2019-09-06 2024-11-11 美商席達拉醫療有限公司 用於治療病毒感染之組合物及方法
US20240285786A1 (en) * 2021-03-11 2024-08-29 Cidara Therapeutics, Inc. Protein-drug conjugates for antiviral therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004507564A (ja) 2000-09-08 2004-03-11 バイオタ、サイアンティフィック、マネージメント、プロプライエタリ、リミテッド 多価ノイラミニダーゼ阻害物質複合体
JP2005511609A (ja) 2001-11-09 2005-04-28 バイオタ、サイアンティフィック、マネージメント、プロプライエタリ、リミテッド 二量体化合物および抗ウイルス薬としてのそれらの使用
WO2018128826A1 (en) 2017-01-06 2018-07-12 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Simon J. F. MACDONALD et al.，Antimicrobial Agentsand Chemotherapy，2004年，Vol. 48, No. 12，pp. 4542-4549
Simon J. F. MACDONALD et al.，Journal of Medicinal Chemistry，2005年，Vol. 48, No. 8，pp. 2964-2971

Also Published As

Publication number Publication date
ECSP22026797A (es) 2022-05-31
CN114980933B (zh) 2025-01-07
WO2021046549A8 (en) 2021-05-20
US20210220478A1 (en) 2021-07-22
KR20220088527A (ko) 2022-06-27
CL2022000531A1 (es) 2022-10-28
IL290792B1 (en) 2026-04-01
PE20221443A1 (es) 2022-09-21
US11510992B1 (en) 2022-11-29
JP2025108559A (ja) 2025-07-23
EP4025256A4 (en) 2023-12-13
WO2021046549A1 (en) 2021-03-11
AU2025263868A1 (en) 2025-11-27
AU2020342649B2 (en) 2025-08-07
CN120168655A (zh) 2025-06-20
CA3153359A1 (en) 2021-03-11
US12427200B2 (en) 2025-09-30
IL290792A (en) 2022-04-01
TWI861205B (zh) 2024-11-11
EP4025256A1 (en) 2022-07-13
US20230398226A1 (en) 2023-12-14
JP2022546609A (ja) 2022-11-04
CO2022003078A2 (es) 2022-07-08
BR112022004058A2 (pt) 2022-05-31
ZA202203681B (en) 2023-11-29
TW202122117A (zh) 2021-06-16
CR20220138A (es) 2022-07-28
MX2022002728A (es) 2022-08-04
PH12022550505A1 (en) 2023-08-23
AU2020342649A1 (en) 2022-03-24
US20260108618A1 (en) 2026-04-23
CN114980933A (zh) 2022-08-30
NZ785415A (en) 2024-07-26

Similar Documents

Publication Publication Date Title
JP7667139B2 (ja) ウイルス感染症の治療のための組成物及び方法
JP7520816B2 (ja) ウイルス感染症の治療のための組成物及び方法
JP2022536740A (ja) ヒト免疫不全ウイルスの治療のための組成物及び方法
US20230082611A1 (en) Compositions and methods for the treatment of respiratory syncytial virus
EP4304659A1 (en) Protein-drug conjugates for antiviral therapy
RU2816717C2 (ru) Композиции и способы для лечения вирусных инфекций
BR112022004058B1 (pt) Conjugado e população de conjugados
EA050683B1 (ru) Композиции и способы лечения вирусных инфекций
HK40075683A (en) Compositions and methods for treatment of viral infections
HK40125780A (zh) 用於治疗病毒感染的组合物和方法
HK40057792A (en) Compositions and methods for the treatment of viral infections
HK40057792B (zh) 用於治疗病毒感染的组合物及方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220610

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250410

R150 Certificate of patent or registration of utility model

Ref document number: 7667139

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150